Ironwood Pharma

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ironwood Pharma excels in Q4 with LINZESS growth and pipeline advancements

Ironwood Pharmaceuticals delivered a strong performance in Q4 2022, driven by LINZESS's growth and pipeline progress. Strategic priorities emphasize profitability and portfolio strength, while challenges around pricing and data release plans require attention. Opportunities exist in expanding LINZESS sales, pediatric indications, and pipeline investments for future growth.

Ironwood Pharma excels in Q1 with LINZESS driving growth

Ironwood Pharma's Q1 2023 showcased strong LINZESS demand, revenue growth, and profitability. The company's strategic focus on LINZESS and innovative pipeline positions it well for sustained success amidst market challenges and growth opportunities.

Ironwood Pharma reports strong Q2 performance and growth opportunities

Ironwood Pharmaceuticals showcased strong performance in Q2 2023, driven by robust U.S. net sales and strategic acquisitions.
While facing challenges in managing the impact of the VectivBio acquisition on EBITDA, the company is well-positioned for growth.
Opportunities lie in expanding LINZESS sales, advancing pipeline candidates like apraglutide, and diversifying into new indications.
Overall, Ironwood's focus on maximizing key products, pipeline advancement, and financial management sets a positive trajectory.

Ironwood Pharma reports strong Q3 performance amidst strategic acquisitions

Ironwood Pharmaceuticals showcased strong performance driven by LINZESS and the acquisition of VectivBio for apraglutide.
While facing challenges in managing financial losses and addressing competitive pressures, Ironwood remains focused on growth opportunities and product development.
Opportunities lie in upcoming Phase III data for apraglutide, pediatric market expansion for LINZESS, and exploring new patient subgroups for apraglutide.

Ironwood Pharma excels in Q4, eyes pediatric market growth

Ironwood Pharmaceuticals showcased robust financial performance, strategic acquisitions, and a focus on pipeline assets during their Q4 2023 earnings call. While facing challenges in defining efficacy and pricing strategies, the company remains optimistic about growth opportunities in the GI market, particularly in the pediatric segment.

Ironwood Pharma reports Q1 growth, prepares for apraglutide launch

Ironwood Pharma's Q1 2024 performance reflects growth in LINZESS prescription volume and positive developments in its pipeline, despite challenges in net sales and guidance adjustments. The company's strategic focus on maximizing LINZESS and preparing for apraglutide's launch presents opportunities for future growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Ironwood Pharmaceuticals (IRWD) reports higher-than-expected earnings and revenues in the fourth quarter.

Ironwood (IRWD) Beats Earnings & Revenues Estimates in Q4

The stock is down year to date, but a strong fourth-quarter performance could quickly turn things around.

Is Ironwood Pharmaceuticals Stock a Buy?

Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.

What's in Store for Ironwood (IRWD) This Earnings Season?

We provide five reasons which makes Ironwood (IRWD) a good investment option in 2020.

5 Reasons Why Ironwood Stock Should Be in Your Portfolio

Does Ironwood Pharmaceuticals (IRWD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Ironwood Pharmaceuticals (IRWD) is a Great Choice

Is  (IRWD) Outperforming Other Medical Stocks This Year?

Is Ironwood Pharmaceuticals (IRWD) Outperforming Other Medical Stocks This Year?

Ironwood Pharmaceuticals, Inc. (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Ironwood Pharmaceuticals

Cardtronics

DexCom

Forterra

NeoPhotonics

Wall Street's impressive bull run is likely to continue in the near term. At this stage, it will be prudent to invest in growth stocks with a favorable Zacks Rank.

5 Best-Performing, Top-Ranked Growth Stocks of November

Virtus LifeSci Biotech Clinical Trials ETF

Loncar Cancer Immunotherapy ETF

Global X Genomics & Biotechnology ETF

iShares U.S. Healthcare Providers ETF

Jounce Therapeutics

Osmotica Pharmaceuticals Plc

ALPS Medical Breakthroughs ETF

Select Medical Holdings

Healthcare bounced back with an outperformance starting the fourth quarter.

Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD

As of late, it has definitely been a great time to be an investor in Ironwood Pharmaceuticals, Inc. (IRWD).

Ironwood Pharmaceuticals, Inc. (IRWD) Shares March Higher, Can It Continue?

Journey Medical Corp

GlycoMimetics

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

Rigel Pharmaceuticals

SPDR S&P Pharmaceuticals ETF

Pharma sector wins in October, making these ETFs and stocks winners.

Pharma Sector Tops in October: Best ETFs & Stocks

Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.

Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Mark Mallon on Q3 2019 Results - Earnings Call Transcript

Ironwood (IRWD) delivered earnings and revenue surprises of 300.00% and 36.62%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings and Revenue Estimates

Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.

Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates

The drugmaker delivered its first-ever quarterly profit and trounced Wall Street top- and bottom-line estimates.

Ironwood Pharmaceuticals' Blowout Q2 Results: What You'll Want to Know

Ironwood Pharmaceuticals' (IRWD) CEO Mark Mallon on Q2 2019 Results - Earnings Call Transcript

Ironwood (IRWD) delivered earnings and revenue surprises of 214.29% and 12.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Top Estimates

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Ironwood (IRWD) and Allergan's Linzess meets the goal in a late-stage study for treating adult patients with IBS-C. Shares rise as the drug reduces bloating, pain and discomfort in IBS-C patients.

Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients

Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.

Ironwood Initiates Dosing in Mid-Stage Study for MD-7246

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report?

An SEC filing shows an activist investor is building a sizable position in the company.

Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Mark Mallon on Q1 2019 Results - Earnings Call Transcript

Ironwood (IRWD) misses on both earnings and sales in the first quarter. The company completes its separation into two entities.

News for Ironwood Pharma Stock (IRWD)